<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01432223</url>
  </required_header>
  <id_info>
    <org_study_id>OMC-BC01</org_study_id>
    <secondary_id>UMIN000006288</secondary_id>
    <nct_id>NCT01432223</nct_id>
  </id_info>
  <brief_title>Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab</brief_title>
  <official_title>Phase II Study of Primary Chemotherapy With Anthracycline-based Regimen Followed by Nab-paclitaxel and Trastuzumab in Patients With HER2 Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osaka Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy in terms of the pathological complete
      response (pCR) rate and the efficacy to preoperative administration of Anthracycline-based
      regimen followed by Nab-paclitaxel and Trastuzumab in patients with HER2 positive operable
      breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four cycles of anthracycline-based regimen followed by four cycles of Nab-paclitaxel and
      Trastuzumab are administrated.

      Anthracycline-based regimen (d1, q3w):

      EC (Epirubicin 90mg/m2 and Cyclophosphamide 600mg/m2) AC (Doxorubicin 60mg/m2 and
      Cyclophosphamide 600mg/m2) FEC (Fluorouracil 500mg/m2, Epirubicin 100mg/m2 and
      Cyclophosphamide 500mg/m2)

      Nab-paclitaxel 260mg/m2 (d1, q3w)

      Trastuzumab (d1, q3w) is given at a dose of 8 mg/kg IV on day 1 of the first treatment cycle
      over 90 min, and subsequently given at a dose of 6 mg/kg over 30 min.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pathological complete response rate</measure>
    <time_frame>1 year from last patient enrolled</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years from the last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>After the protocol therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>After the protocol therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast-conserving surgery rate</measure>
    <time_frame>After the protocol therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Within the protocol thepapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Breast Cancer</condition>
  <condition>HER-2 Positive Breast Cancer</condition>
  <condition>Effects of Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel q3w 260mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Nab-paclitaxel 260mg/m2 q3w</description>
    <arm_group_label>Nab-paclitaxel</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed invasive breast cancer

          -  T1c-3 N0-2a

          -  Confirmed of hormonal receptor status

          -  HER2 positive confirmed by IHC 3+ or FISH+

          -  LVEF &gt; 50% by echocardiogram or MUGA

          -  Adequate EKG

          -  No prior treatment for breast cancer

          -  PS 0-1

          -  Required baseline laboratory data WBC &gt; 4,000/mm3 and Neut &gt; 2,000/mm3 PLT &gt;
             100,000/mm3 Hb &gt; 9.0g/dl AST and ALT &lt; ULNx2.5 T-Bil &lt; 1.5mg/dl Serum creatinin &lt;
             1.5mg/dl

          -  Written informed consent

        Exclusion Criteria:

          -  With history of hypersensitivity reaction for important drug in this study

          -  With history of invasive breast cancer

          -  Bilateral invasive breast cancer

          -  Patients with medical conditions that renders them intolerant to primary chemotherapy
             and related treatment, including infection, diarrhea, intestinal paralysis, severe
             Diabetes Mellitus

          -  Positive for HBs antigen and with history of HVB

          -  With history of congestive heart failure, uncontrolled or symptomatic angina pectoris,
             arrhythmia or myocardial infarction, poorly controlled hypertension

          -  With severe edema

          -  With severe peripheral neuropathy

          -  With severe psychiatric disorder

          -  Pregnant or nursing women

          -  Cases who physician judged improper to entry this trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitsuhiko Iwamoto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osaka Medical College</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>5698686</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Tanaka S, Iwamoto M, Kimura K, Matsunami N, Morishima H, Yoshidome K, Nomura T, Morimoto T, Yamamoto D, Tsubota Y, Kobayashi T, Uchiyama K. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer. Clin Breast Cancer. 2015 Jun;15(3):191-6. doi: 10.1016/j.clbc.2014.12.003. Epub 2014 Dec 24.</citation>
    <PMID>25579459</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2011</study_first_submitted>
  <study_first_submitted_qc>September 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2011</study_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Osaka Medical College</investigator_affiliation>
    <investigator_full_name>Satoru Tanaka</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Trastuzumab</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Primary chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

